Hinge Health

Deliberate B, and the reasoning is the substance of this record. The computer vision is real and deep: the company acquired wrnch, a leading human motion computer vision platform, stated it thereby held the largest computer vision team in digital health, and built TrueMotion to detect 87 body reference points from an ordinary phone camera with no specialised hardware. That is a genuine technical asset, not a label. But the business is a digital MSK CLINIC: revenue comes from delivering care through employed physicians, physical therapists, nurses and health coaches, with the technology making that care team more effective and scalable. The AI is a differentiating layer on a care delivery organisation rather than the product being sold. Not C, because unlike the rejected services businesses the technology is proprietary, substantial and central to the clinical claim; not A, because remove the AI and a care business remains, whereas removing the model from Elucid or Lyssn leaves nothing.

AI is explicitly positioned as complementing rather than replacing clinician judgement, with technology surfacing timely insights while physical therapists set and adjust care plans, and the company has published AI care principles that include continuous governance and evaluation of AI systems as clinical evidence and regulatory standards evolve. Publishing principles at all is more than most peers do. Graded B rather than A because Robin, the AI care assistant, interacts directly with members providing instant support, and no escalation logic, containment rate or boundary description was located for what Robin handles autonomously versus what it routes to a clinician. In a population presenting with pain, where a small fraction of presentations are red flags requiring urgent assessment, that escalation boundary is the safety-critical disclosure and it is absent.

More specific than most consumer-facing digital health vendors. The provenance is traceable to the wrnch acquisition, the mechanism is named concretely at 87 body reference points tracked via phone camera, and the measured outputs are enumerated as joint angles, symmetry and endurance. Graded B rather than A because HingeScore, the composite metric now central to the outcome claim, has no published derivation, weighting or validation methodology located, and it blends objective motion capture with subjective questionnaire responses in an undisclosed ratio. A proprietary composite score presented as an outcome measure needs its construction published.

Substantial and peer reviewed, but measuring the programme rather than the AI, which is the distinction that caps this grade. The company reports three randomised controlled trials, a large-scale study of around 10,000 participants, a 12 month outcomes study published in BMC Musculoskeletal Disorders reporting pain reduced by more than half and sustained at one year, and what it describes as the only study of a digital MSK programme in an older adult population. That is a stronger evidence base than most care delivery businesses assemble. Two honest limits keep it at B. First, the trials evaluate the overall care programme, exercise therapy plus clinician contact plus coaching, so they do not isolate any contribution from the computer vision layer, and no validation of TrueMotion measurement accuracy against laboratory motion capture or goniometry was located. Second, no head-to-head trial exists against Sword Health or other digital MSK competitors, a gap third party sources state explicitly, so relative effectiveness in this category is genuinely unestablished.

The published AI care principles are a genuine positive and include continuous governance commitments. But the data type here is unusually sensitive and the disclosure does not match it: the product captures video of members exercising in their own homes, and no published position was located on whether that video is retained, for how long, whether it is used to train models, or whether it is processed on device or in the cloud. Home video of a person's body is among the most intimate data any vendor in this index collects, and it is being gathered from millions of employer-sponsored members who may perceive participation as workplace-adjacent. The absence of an explicit published video retention and training-use policy is a material gap.

Operates as a healthcare provider organisation contracting with self-insured employers and health plans, so HIPAA obligations clearly apply, but no published BAA terms or posture statement was located at the time of review.

No specific third party attestation such as SOC 2 Type II or HITRUST was retrieved at the time of review, notable for an NYSE listed company serving large employers and health plans.

A split position that must not be conflated, and the distinction runs the opposite way to most index vendors. Enso, the wearable electrical nerve stimulation device, is FDA cleared. The AI is not: TrueMotion, Movement Analysis, HingeScore and Robin are not represented as FDA cleared or regulated, and they are the components this vendor is indexed for. So the company holds a real clearance, but on the hardware rather than on the software the index grades. Graded C rather than Not Rated because, unlike Eleos or Lyssn which sit cleanly outside device regulation, a computer vision system producing joint angle measurements and a composite joint health score used to inform treatment decisions sits closer to the Software as a Medical Device boundary, and no located material addresses where the company considers that line to fall.

Published AI care principles including continuous governance are more than most peers offer, but no demographic subgroup performance analysis was located and the exposure for this technology is specific and well documented. Pose estimation and computer vision body tracking have known performance variation across skin tone, body size, clothing, mobility aids and home lighting conditions. A member whose movement is tracked less accurately receives worse feedback and a less accurate HingeScore, and the populations most likely to be affected substantially overlap with those already experiencing worse musculoskeletal outcomes. Nothing located addresses whether TrueMotion accuracy has been evaluated across these strata. Compare Cognivue's FOCUS study as the standard this axis should be graded against.

No named EHR integrations located. The commercial model runs through employers and health plans rather than provider organisations, so the integration surface is benefits administration and eligibility rather than the clinical record, and no specific integration disclosure was retrieved.

The strongest axis on this record and a real technical achievement. TrueMotion runs on the camera in a member's existing personal device with no specialised equipment, sensors or hardware required, tracking 87 body points in three dimensions. Removing the hardware dependency is what makes home-based objective movement assessment viable at population scale, and it contrasts directly with Cognivue in this same batch, which requires a dedicated calibrated device. Wearable hardware exists as an adjunct via Enso but is not required for the motion tracking. No data residency disclosure located, which is the only thing keeping this from being unqualified.

No pricing published. The product is sold to self-insured employers and health plans as a benefit, so members do not see a price and the buyer terms are negotiated and confidential. Third party comparison notes that competitors such as Kaia Health publish flat consumer subscription pricing while Hinge's cost depends entirely on employer or plan arrangement. For an NYSE listed company, contract economics are partially inferable from public filings, but nothing about per-member pricing or the fee structure is directly disclosed.

Broad within musculoskeletal care and expanding: acute and chronic MSK conditions, pre and post surgical pathways, pelvic health, and integration of behavioural health support reflecting the biopsychosocial reality that physical pain and psychological distress are interconnected. TrueMotion specifically extends tracking to difficult regions including head, neck and hands, and the company reports roughly 75 percent of members experience pain in more than one body area, which the whole-body tracking addresses. Reach is very large across employers and health plans. Graded B rather than A because it remains one clinical domain delivered through one channel, employer and plan sponsored benefits, with no provider or direct clinical channel located.